All news

News

Lilly’s retatrutide cuts knee arthritis pain in trial — what TRIUMPH-4 data means for cash buyers

Eli Lilly's retatrutide trial shows a 25% weight loss and a 50% drop in knee osteoarthritis pain. Learn what this next-gen trial means for US cash buyers.

By CompareRx Editorial Team · Medically reviewed by CompareRx Medical Review Desk
Published
A close-up of a person holding their knee in pain, representing knee osteoarthritis clinical trial results.

Key takeaways

  • Eli Lilly's experimental triple-agonist drug retatrutide reduced knee osteoarthritis pain and disability by roughly half in a phase 3 trial.
  • Pain Reduction: Baseline pain scores averaged 5.95. By week 68, pain scores dropped by 4.48 points in the 9 mg group and 4.41 points in the 12 mg group, compared to a decline of only 2.43 points in the placebo group.
  • Physical Function: Baseline disability scores averaged 5.75. Disability scores improved by 4.14 points with the 9 mg dose and 4.20 points with the 12 mg dose, compared to a 2.06-point improvement in the placebo group.

Compare providers side by side or read the full GLP-1 guides.

Key takeaways

  • Eli Lilly's experimental triple-agonist drug retatrutide reduced knee osteoarthritis pain and disability by roughly half in a phase 3 trial.

What happened

At the American College of Rheumatology annual meeting in November 2026, researchers presented phase 3 clinical trial data showing that Eli Lilly’s experimental triple-agonist drug, retatrutide, significantly reduces knee osteoarthritis pain and physical disability. The trial, known as TRIUMPH-4, evaluated patients over 68 weeks and was simultaneously published in the New England Journal of Medicine. Participants taking retatrutide lost more than 25% of their total body weight, marking one of the highest weight-reduction rates recorded in a phase 3 obesity trial.

Why it matters

For the millions of Americans living with joint pain and obesity, these findings introduce a powerful orthopedic benefit to the next-generation GLP-1 market. Knee osteoarthritis (OA) is heavily aggravated by excess body weight, which increases the mechanical load on joint cartilage.

By demonstrating that retatrutide can cut pain scores and physical disability roughly in half, this clinical trial positions "triple-G" drugs as multi-benefit treatments. For cash-paying US consumers who navigate online telehealth platforms, these orthopedic benefits add a compelling justification for out-of-pocket costs, especially for patients who may not meet strict insurance coverage requirements for weight loss alone.

What the data says

The TRIUMPH-4 trial enrolled 445 patients with obesity (defined as a body mass index of 27 or higher) and confirmed knee osteoarthritis across the US, Canada, Mexico, Australia, and Spain. According to lead investigator Thomas Conaghan, MBBS, PhD, of the University of Leeds, participants had an average baseline BMI of 40.4 and an average body weight of 249 pounds (113 kg). Crucially, 64% of the participants had advanced joint damage, classified as Kellgren-Lawrence grade 3.

Researchers randomized patients to receive a weekly subcutaneous injection of either a placebo, a 9 mg dose of retatrutide, or a 12 mg dose of retatrutide. All participants received physical activity and dietary counseling.

The study measured pain and disability using the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), where higher scores indicate worse pain and disability:

  • Pain Reduction: Baseline pain scores averaged 5.95. By week 68, pain scores dropped by 4.48 points in the 9 mg group and 4.41 points in the 12 mg group, compared to a decline of only 2.43 points in the placebo group.
  • Physical Function: Baseline disability scores averaged 5.75. Disability scores improved by 4.14 points with the 9 mg dose and 4.20 points with the 12 mg dose, compared to a 2.06-point improvement in the placebo group.
  • Weight Loss: Participants on retatrutide lost more than 25% of their body weight at 68 weeks. Weight loss was visible early, with both retatrutide groups averaging nearly a 7% reduction by week 8 (compared to 2% for placebo). The weight loss was so substantial that some participants withdrew from the trial because they felt they were losing too much weight.

To explain the pain relief, the study authors noted that weight reduction decreases mechanical loading on the knee, with the load reduction acting as a multiple of the actual weight lost. Additionally, they suggested that reducing adipose (fat) tissue may lower systemic inflammatory mediators.

How it compares

Retatrutide is a "triple-agonist" or "triple-G" molecule. Unlike single-agonist medications like semaglutide (Wegovy and Ozempic) which only target the GLP-1 receptor, or dual-agonists like tirzepatide (Zepbound and Mounjaro) which target GLP-1 and GIP, retatrutide targets three metabolic pathways: GLP-1, GIP, and glucagon.

This triple-action mechanism generates sharper weight loss than its predecessors. While tirzepatide average weight loss typically hovers around 20% to 22.5% in clinical trials, retatrutide’s 25% threshold represents a new clinical benchmark.

For cash buyers evaluating telehealth providers, this clinical gap is significant. Currently, patients paying out-of-pocket for brand-name Wegovy or Zepbound face retail costs ranging from $1,000 to $1,350 per month, though online telehealth companies often offer compounded alternatives for $250 to $400 per month. When retatrutide eventually hits the market, its superior weight-loss efficacy and direct orthopedic benefits will likely position it as a premium option, shaping how cash-paying buyers calculate the value of their monthly treatment.

How this fits the bigger picture

The TRIUMPH-4 data marks another step forward in Eli Lilly’s effort to demonstrate that incretin-based therapies do far more than lower numbers on a scale. We have previously covered how clinical trials are expanding the medical case for these therapies beyond simple weight loss.

For instance, our coverage of the ASRM tirzepatide trial highlighted how dual-agonist drugs improve menstrual regularity for PCOS patients. Similarly, we analyzed how clinical advancements like the orforglipron sleep apnea trial are establishing secondary cardiovascular and respiratory benefits.

This trial adds knee osteoarthritis to the growing list of co-morbidities that next-generation GLP-1s can treat. However, as retatrutide continues its clinical development, some eager consumers have bypassed the regulatory process entirely. We have previously reported on the risks of this trend, such as grey-market retatrutide side effects reported on Reddit, which include unexpected appetite surges and sleep disruptions. The formal data from TRIUMPH-4 highlights the clinical efficacy of the drug when administered under proper medical supervision.

What happens next

Retatrutide remains an investigational drug and is not yet approved by the US Food and Drug Administration (FDA) for weight loss or osteoarthritis. The TRIUMPH-4 trial is part of Eli Lilly's broader phase 3 clinical program, which will continue to report safety and efficacy data.

Researchers noted that further studies are needed to determine the precise mechanisms behind retatrutide's pain reduction, and to evaluate whether the drug can serve as a direct disease-modifying therapy that prevents joint cartilage degradation. Additionally, future trials must examine how the drug affects non-obese patients with osteoarthritis to ensure it does not cause unwanted weight loss in those who do not need it.

CompareRx provides factual information on telehealth providers and clinical research for educational purposes. We do not provide medical advice. Consult a licensed healthcare professional before starting any weight-loss or medication regimen.

Find the provider that fits your budget

Compare 100+ online GLP-1 providers on true monthly cost, or get your top 3 matches in 90 seconds.

More from the newsroom

Popular comparisons

Sources

Community

What do you make of this?

Add your take, ask a question, or tell us what you're seeing with your own provider — our editors read every thread.

Medical disclaimer: CompareRx.org is an independent comparison site and publisher. This article is informational only, is not medical advice, and is not a substitute for care from a licensed clinician. Read our medical disclaimer, editorial policy and affiliate disclosure.